Hot Investor Mandate 1: China-based Fund Seeks Therapeutic Opportunities Worldwide

17 Mar

A sector-exclusive life sciences venture and growth equity fund based in Shanghai, China, manages 5 funds with AUM of USD 500M. The firm currently investing from a fund that closed in April 2015, backed by a pharma firm as well as a number of world-class institutional investors. The firm is stage agnostic, investing in early, growth, and up to pre-IPO opportunities. The firm’s team of investment professionals all have a healthcare background. Investment size is USD 5-45 million per company. The firm prefers to lead or co-lead a financing round, and typically requires a board seat. With both USD and RMB funds, the firm on China but also considers opportunities from US, Canada, and Europe.

The firm focuses 75% on therapeutics, with an emphasis on oncology, cell therapy, and biologics. Small molecules are less of interest. The firm is also interested in medical devices, diagnostics, animal health. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: